jens juul holst glp 1 "In India, [#GLP-1 receptor agonists] are now sold at as low as 14% of the list price. Slowly but surely, we will get there with sufficient amounts and much lower prices.", Holst, MD, PhD, Media Centre | EASD

Image Credit: zimmytws / Shutterstock In a recent article published in the journal JMIR Infodemiology , researchers analyzed public Facebook posts to examine public discussion of adverse effects associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs)

Selective study citation Marketing highlights research showing that specific compounds can increase GLP-1 secretion, while omitting context about magnitude, duration, or clinical significance

Results: We observe that METTL3 expression is significantly upregulated in human HCC tissues which is associated with poor patient survival

We dont know. Whats happening on the federal level with respect to peptides

Benefits of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial